SECENDS - LLY

2025

Q4 3 filings

Nov

New Board Director Elected

Carolyn R. Bertozzi, Ph.D elected to board effective Dec 8, 2025

8-K

Oct

Q3 2025 Results

Unable to extract specific revenue and EPS figures from XBRL metadata

10-Q

Oct

Q3 Earnings

Q3 2025 financial results announced

8-K

Q3 3 filings

Aug

Multi-Tranche Debt Offering

$6.75B notes issued across 7 tranches, rates 4.0%-5.65%

8-K

Aug

Q2 2025 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Aug

Q2 Earnings

Q2 2025 financial results for quarter ended June 30, 2025

8-K

Q2 3 filings

May

Annual Shareholder Meeting

846.7M shares voted (89% turnout), classified board elimination failed

8-K

May

Q1 2025 Results

Unable to extract - financial data not visible in provided content

10-Q

May

Q1 2025 Earnings

Q1 2025 financial results announced

8-K

Q1 5 filings

Mar

2025 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled

DEF 14A

Feb

FY24 2024 Results

Unable to extract specific revenue/EPS figures from provided XBRL metadata

📌 Unable to extract specific business milestones from provided XBRL metadata - actual financial statement content needed for analysis

10-K

Feb

Multi-Tranche Bond Issuance

$6.46B notes across 6 tranches, rates 4.55%-5.60%

8-K

Feb

Q4 2024 Earnings

Financial results for quarter and year ended December 31, 2024

8-K

Jan

2025 Guidance Update

Updated 2024 earnings guidance and 2025 revenue guidance at JPM Conference

8-K

2024

Q4 3 filings

Nov

Board Changes - New Director Added, Director Resigned

Jon Moeller (P&G CEO) elected to board Dec 1, Karen Walker resigned Dec 31

8-K

Oct

Q3 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Oct

Q3 Earnings

Q3 2024 financial results for quarter ended September 30, 2024

8-K

Q3 6 filings

Sep

CFO Appointed

Lucas Montarce elected EVP/CFO, $1M base salary

8-K

Aug

Director Retirement

Dr. Marschall S. Runge retired from Board effective August 31, 2024

8-K

Aug

Debt Offering

$5B notes offering across 5 series, rates 4.15%-5.20%

8-K

Aug

Q2 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Aug

Q2 2024 Earnings

Financial results for quarter ended June 30, 2024

8-K

Jul

CFO Departed, Interim CFO Appointed

Anat Ashkenazi resigned as CFO, Gordon Brooks named interim CFO effective July 15, 2024

8-K

Q2 4 filings

Jun

CFO Resigned

Anat Ashkenazi out, serving through July 2024

8-K

May

Annual Shareholder Meeting

90% turnout, 4 directors elected, compensation approved, governance proposals failed

8-K

Apr

Q1 2024 Results

Unable to extract revenue and EPS figures from provided XBRL tags

10-Q

Apr

Q1 2024 Earnings

Q1 2024 financial results announced

8-K

Q1 3 filings

Mar

2024 Proxy Statement

CEO comp: Not disclosed in excerpt, Say-on-pay: Not disclosed in excerpt

DEF 14A

Feb

FY2023 2023 Results

Rev $34.1B, EPS $5.80 (Rev +20% YoY from $28.5B)

📌 Mounjaro diabetes drug revenue surged to $5.2B in 2023 vs $1.0B in 2022, driving growth acceleration

10-K

Feb

Debt Offering

$6.5B multi-tranche notes, rates 4.5%-5.1%

8-K